The genome and epigenome of malignant melanoma
- PMID: 18042149
- DOI: 10.1111/j.1600-0463.2007.apm_855.xml.x
The genome and epigenome of malignant melanoma
Abstract
Malignant melanoma originates in melanocytes, the pigment-producing cells of the skin and eye, and is one of the most deadly human cancers with no effective cure for metastatic disease. Like many other cancers, melanoma has both environmental and genetic components. For more than 20 years, the melanoma genome has been subject to extensive scrutiny, which has led to the identification of several genes that contribute to melanoma genesis and progression. Three molecular pathways have been found to be nearly invariably dysregulated in melanocytic tumors, including the RAS-RAF-MEK-ERK pathway (through mutation of BRAF, NRAS or KIT), the p16 INK4A-CDK4-RB pathway (through mutation of INK4A or CDK4) and the ARF-p53 pathway (through mutation of ARF or TP53). Less frequently targeted pathways include the PI3K-AKT pathway (through mutation of NRAS, PTEN or PIK3CA) and the canonical Wnt signaling pathway (through mutation of CTNNB1 or APC). Beyond the specific and well-characterized genetic events leading to activation of proto-oncogenes or inactivation of tumor suppressor genes in these pathways, systematic high-resolution genomic analysis of melanoma specimens has revealed recurrent DNA copy number aberrations as well as perturbations of DNA methylation patterns. Melanoma provides one of the best examples of how genomic analysis can lead to a better understanding of tumor biology. We review current knowledge of the genes involved in the development of melanoma and the molecular pathways in which these genes operate.
Similar articles
-
KIT pathway alterations in mucosal melanomas of the vulva and other sites.Clin Cancer Res. 2011 Jun 15;17(12):3933-42. doi: 10.1158/1078-0432.CCR-10-2917. Clin Cancer Res. 2011. PMID: 21680547
-
Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.Oncol Rep. 2005 Dec;14(6):1481-5. Oncol Rep. 2005. PMID: 16273242
-
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669. Cancer Res. 2004. PMID: 15313890
-
MicroRNAs in the pathogenesis of malignant melanoma.J Eur Acad Dermatol Venereol. 2013 Feb;27(2):142-50. doi: 10.1111/j.1468-3083.2012.04579.x. Epub 2012 May 23. J Eur Acad Dermatol Venereol. 2013. PMID: 22621697 Review.
-
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
Cited by
-
Genome-wide screen of promoter methylation identifies novel markers in melanoma.Genome Res. 2009 Aug;19(8):1462-70. doi: 10.1101/gr.091447.109. Epub 2009 Jun 2. Genome Res. 2009. PMID: 19491193 Free PMC article.
-
Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances.Int J Mol Sci. 2021 Jun 15;22(12):6395. doi: 10.3390/ijms22126395. Int J Mol Sci. 2021. PMID: 34203771 Free PMC article. Review.
-
Simultaneous Profiling of DNA Mutation and Methylation by Melting Analysis Using Magnetoresistive Biosensor Array.ACS Nano. 2017 Sep 26;11(9):8864-8870. doi: 10.1021/acsnano.7b03053. Epub 2017 Sep 13. ACS Nano. 2017. PMID: 28832112 Free PMC article.
-
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.Biochem Pharmacol. 2010 Sep 1;80(5):624-37. doi: 10.1016/j.bcp.2010.04.029. Epub 2010 May 9. Biochem Pharmacol. 2010. PMID: 20450891 Free PMC article. Review.
-
NS398 induces apoptosis in non-small cell lung cancer cells.J Cancer Res Clin Oncol. 2012 Jan;138(1):119-24. doi: 10.1007/s00432-011-1080-3. Epub 2011 Nov 3. J Cancer Res Clin Oncol. 2012. PMID: 22048655
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous